Liposome-encapsulated aprotinin biodistribution in mice: Side-by-side comparison with free drug formulation.

Injuries of the respiratory system caused by viral infections (e.g., by influenza virus, respiratory syncytial virus, metapneumovirus, or coronavirus) can lead to long-term complications or even life-threatening conditions.

Aprotinin-Drug against Respiratory Diseases.

Aprotinin (APR) was discovered in 1930. APR is an effective pan-protease inhibitor, a typical "magic shotgun". Until 2007, APR was widely used as an antithrombotic and anti-inflammatory drug in cardiac and noncardiac surgeries for reduction of bleeding and thus limiting the need for blood transfusion.

The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2.

The efficacy of aprotinin combinations with selected antiviral-drugs treatment of influenza virus and coronavirus (SARS-CoV-2) infection was studied in mice models of influenza pneumonia and COVID-19. The high efficacy of the combinations in reducing virus titer in lungs and body weight loss and in increasing the survival rate were demonstrated. This preclinical study can be considered a confirmatory step before introducing the combinations into clinical assessment.

Synthesis and downconversion photoluminescence of Erbium-doped chalcohalide glasses of AgCl(I)-GaS-LaS systems.

Erbium-doped chalcohalide glasses of the ()-- systems were synthesized by using the melting-cooling method. The introduction of a halide component leads to a decrease in the absorption coefficient, and the addition of erbium leads to the emergence of narrow absorption bands associated with transitions in the f-shell of ions. Five PL bands were detected in erbium-doped samples when excited by a laser with a 532 nm wavelength, the most intense of which at 980 nm and 1540 nm are promising for use in optical amplifiers and fiber optic networks.

[THE RESULTS OF SCREENING OF DONATED BLOOD IN THE UKRAINE THE PRESENCE OF MARKERS HEMOTRANSMISYVNYH INFECTIONS IN 2010-2012 YEARS].

Prevalence level of HIV markers among blood and blood coMponent donors in European region of WHO increased from 8.3 to 10.3 positive cases per: 100,000 donations diring 2001-2006.